In last trading session, Prime Medicine Inc. (NASDAQ:PRME) saw 0.14 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $19.69 trading at $0.55 or 2.87% at ring of the bell on the day assigns it a market valuation of $1.90B. That closing price of PRME’s stock is at a discount of -10.36% from its 52-week high price of $21.73 and is indicating a premium of 26.26% from its 52-week low price of $14.52. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.17 million shares which gives us an average trading volume of 461.25K if we extend that period to 3-months.
For Prime Medicine Inc. (PRME), analysts’ consensus is at an average recommendation of an Overweight while assigning it a mean rating of 2.20. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Prime Medicine Inc. (NASDAQ:PRME) trade information
Upright in the green during last session for gaining 2.87%, in the last five days PRME remained trading in the green while hitting it’s week-highest on Wednesday, 11/23/22 when the stock touched $19.69 price level, adding 3.62% to its value on the day. Prime Medicine Inc.’s shares saw a change of 28.11% in year-to-date performance and have moved 8.07% in past 5-day. Prime Medicine Inc. (NASDAQ:PRME) showed a performance of 22.68% in past 30-days.
Wall Street analysts have assigned a consensus price target of $24.25 to the stock, which implies a rise of 18.8% to its current value. Analysts have been projecting $22.00 as a low price target for the stock while placing it at a high target of $27.00. It follows that stock’s current price would drop -37.13% in reaching the projected high whereas dropping to the targeted low would mean a loss of -11.73% for stock’s current value.
Prime Medicine Inc. is more likely to be releasing its next quarterly report in December and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Prime Medicine Inc. (NASDAQ:PRME)’s Major holders
Insiders are in possession of 29.62% of company’s total shares while institution are holding 0.00 percent of that, with stock having share float percentage of 0.00%. Investors also watch the number of corporate investors in a company very closely, which is 0.00% institutions for Prime Medicine Inc. that are currently holding shares of the company.